Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease)

Author(s): Francyne Kubaski, Filippo Vairo, Guilherme Baldo, Fabiano de Oliveira Poswar, Amauri Dalla Corte and Roberto Giugliani*

Volume 26, Issue 40, 2020

Page: [5100 - 5109] Pages: 10

DOI: 10.2174/1381612826666200724161504

Price: $65

Abstract

Background: Mucopolysaccharidosis type II (Hunter syndrome, or MPS II) is an X-linked lysosomal disorder caused by the deficiency of iduronate-2-sulfatase, which leads to the accumulation of glycosaminoglycans (GAGs) in a variety of tissues, resulting in a multisystemic disease that can also impair the central nervous system (CNS).

Objective: This review focuses on providing the latest information and expert opinion about the therapies available and under development for MPS II.

Methods: We have comprehensively revised the latest studies about hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT - intravenous, intrathecal, intracerebroventricular, and intravenous with fusion proteins), small molecules, gene therapy/genome editing, and supportive management.

Results and Discussion: Intravenous ERT is a well-established specific therapy, which ameliorates the somatic features but not the CNS manifestations. Intrathecal or intracerebroventricular ERT and intravenous ERT with fusion proteins, presently under development, seem to be able to reduce the levels of GAGs in the CNS and have the potential of reducing the impact of the neurological burden of the disease. Gene therapy and/or genome editing have shown promising results in preclinical studies, bringing hope for a “one-time therapy” soon. Results with HSCT in MPS II are controversial, and small molecules could potentially address some disease manifestations. In addition to the specific therapeutic options, supportive care plays a major role in the management of these patients.

Conclusion: At this time, the treatment of individuals with MPS II is mainly based on intravenous ERT, whereas HSCT can be a potential alternative in specific cases. In the coming years, several new therapy options that target the neurological phenotype of MPS II should be available.

Keywords: Mucopolysaccharidosis, Hunter syndrome, iduronate-2-sulfatase, glycosaminoglycans, enzyme replacement therapy, gene therapy, hematopoietic stem cell transplantation.

« Previous Next »
[1]
Hunter C. A rare disease in two brothers. Proc R Soc Med 1917; 10(Sect Study Dis Child): 104-16.
[http://dx.doi.org/10.1177/003591571701001833] [PMID: 19979883]
[2]
Neufeld E, Muenzer J. The Mucopolysaccharidoses | The Online Metabolic and Molecular Bases of Inherited Disease | OMMBID | McGraw-Hill Medical. 8th ed New york: McGraw-Hill 2001. Available from: https://ommbid.mhmedical.com/ content.aspx?bookid=971&sectionid=62642135&jumpsectionID=62642144
[3]
Fujitsuka H, Sawamoto K, Peracha H, et al. Biomarkers in patients with mucopolysaccharidosis type II and IV. Mol Genet Metab Rep 2019; 19100455
[http://dx.doi.org/10.1016/j.ymgmr.2019.100455] [PMID: 30775257]
[4]
Pinto LLC, Vieira TA, Giugliani R, Schwartz IVD. Expression of the disease on female carriers of X-linked lysosomal disorders: A brief review. Orphanet J Rare Dis 2010; 5: 14.
[http://dx.doi.org/10.1186/1750-1172-5-14] [PMID: 20509947]
[5]
Giugliani R, Federhen A, Michelin-Tirelli K, Riegel M, Burin M. Relative frequency and estimated minimal frequency of Lysosomal Storage Diseases in Brazil: Report from a Reference Laboratory. Genet Mol Biol 2017; 40(1): 31-9.
[http://dx.doi.org/10.1590/1678-4685-gmb-2016-0268] [PMID: 28304074]
[6]
Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr 2012; 171(4): 631-9.
[http://dx.doi.org/10.1007/s00431-012-1703-y] [PMID: 22383073]
[7]
Giugliani R, Brusius-Facchin AC, Moura De Souza CF, et al. Diagnosis and therapy options in mucopolysaccharidosis II (Hunter syndrome). Expert Opin Orphan Drugs 2015; 3: 141-50.
[8]
Fratantoni JC, Hall CW, Neufeld EF. hurler and hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science (80) 1968; 162: 570-2.
[9]
Araya K, Sakai N, Mohri I, et al. Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation. Mol Genet Metab 2009; 98(3): 255-63.
[PMID: 19556155]
[10]
Boelens JJ, van Hasselt PM. neurodevelopmental outcome after hematopoietic cell transplantation in inborn errors of metabolism: current considerations and future perspectives. Neuropediatrics 2016; 47(5): 285-92.
[http://dx.doi.org/10.1055/s-0036-1584602] [PMID: 27308871]
[11]
Seto T, Kono K, Morimoto K, et al. Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 2001; 50(1): 79-92.
[http://dx.doi.org/10.1002/ana.1098] [PMID: 11456314]
[12]
Tanaka A, Okuyama T, Suzuki Y, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan. Mol Genet Metab 2012; 107(3): 513-20.
[http://dx.doi.org/10.1016/j.ymgme.2012.09.004] [PMID: 23022072]
[13]
Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998; 91(7): 2601-8.
[http://dx.doi.org/10.1182/blood.V91.7.2601] [PMID: 9516162]
[14]
Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant 2000; 25(10): 1093-7.
[http://dx.doi.org/10.1038/sj.bmt.1702397] [PMID: 10828871]
[15]
Ito K, Ochiai T, Suzuki H, Chin M, Shichino H, Mugishima H. The effect of haematopoietic stem cell transplant on papules with ‘pebbly’ appearance in Hunter’s syndrome. Br J Dermatol 2004; 151(1): 207-11.
[http://dx.doi.org/10.1111/j.1365-2133.2004.05944.x] [PMID: 15270893]
[16]
Ochiai T, Ito K, Shichino H, Chin M, Mugishima H. Ultrastructural findings of cutaneous nerves in patients with Hunter’s syndrome following hematopoietic stem cell transplant. Med Mol Morphol 2005; 38(2): 118-22.
[http://dx.doi.org/10.1007/s00795-005-0284-5] [PMID: 15944819]
[17]
Escolar M, Michele PD, Vinod P, Joanne K, Paul S. Neurodevelopmental outcomes of children with MPS II after unrelated umbilical cord blood transplantation. Biol Blood Marrow Transplant 2007; 13: 63.
[18]
Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009; 154(5): 733-7.
[http://dx.doi.org/10.1016/j.jpeds.2008.11.041] [PMID: 19167723]
[19]
Poe M, Escolar M, Kurtzberg J, et al. MPS II: developmental outcomes after hematopoietic stem cell transplantation. Mol Genet Metab 2011; 102: S35-6.
[http://dx.doi.org/10.1016/j.ymgme.2010.11.120]
[20]
Escolar M, Poe M, Rajan D, Szabolcs P. Longterm outcomes of patients receiving umbilical blood stem cell transplantation for MPS II. Mol Genet Metab 2013; 108: S37-8.
[http://dx.doi.org/10.1016/j.ymgme.2012.11.079]
[21]
Annibali R, Caponi L, Morganti A, Manna M, Gabrielli O, Ficcadenti A. Hunter syndrome (Mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation. Minerva Pediatr 2013; 65(5): 487-96.
[PMID: 24056375]
[22]
Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome. Mol Genet Metab Rep 2014; 1: 184-96.
[http://dx.doi.org/10.1016/j.ymgmr.2014.04.001] [PMID: 25061571]
[23]
Tanjuakio J, Suzuki Y, Patel P, et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol Genet Metab 2015; 114(2): 161-9.
[http://dx.doi.org/10.1016/j.ymgme.2014.11.002] [PMID: 25468646]
[24]
Warkentin PI, Dixon MS Jr, Schafer I, Strandjord SE, Coccia PF. Bone marrow transplantation in Hunter syndrome: a preliminary report. Birth Defects Orig Artic Ser 1986; 22(1): 31-9.
[PMID: 3083885]
[25]
Cagle S. Clinical outcomes and biochemical data following hematopoietic stem cell transplantation in a patient with Hunter syndrome. Mol Genet Metab 2015; 114: S28.
[http://dx.doi.org/10.1016/j.ymgme.2014.12.044]
[26]
Wang J, Luan Z, Jiang H, et al. Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-a ten-year report from the China children transplant group. Biol Blood Marrow Transplant 2016; 22(11): 2104-8.
[http://dx.doi.org/10.1016/j.bbmt.2016.08.015] [PMID: 27555533]
[27]
Muschol N, Kohn A, Ulrich K, et al. Clinical outcome after hematopoietic stem cell transplantation in two patients with Hunter syndrome. Mol Genet Metab 2016; 117: S84.
[http://dx.doi.org/10.1016/j.ymgme.2015.12.372]
[28]
Barth AL, de Magalhães TSPC, Reis ABR, et al. Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-up. Mol Genet Metab Rep 2017; 12: 62-8.
[http://dx.doi.org/10.1016/j.ymgmr.2017.05.010] [PMID: 28649514]
[29]
Kubaski F, Yabe H, Suzuki Y, et al. Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II. Biol Blood Marrow Transplant 2017; 23(10): 1795-803.
[http://dx.doi.org/10.1016/j.bbmt.2017.06.020] [PMID: 28673849]
[30]
Barth AL, Horovitz DDG. Hematopoietic stem cell transplantation in mucopolysaccharidosis type II. J Inborn Errors Metab Screen 2018; 6232640981877909
[31]
Bergstrom SK, Quinn JJ, Greenstein R, Ascensao J. Long-term follow-up of a patient transplanted for Hunter’s disease type IIB: a case report and literature review. Bone Marrow Transplant 1994; 14(4): 653-8.
[PMID: 7858546]
[32]
Imaizumi M, Gushi K, Kurobane I, et al. Long-term effects of bone marrow transplantation for inborn errors of metabolism: a study of four patients with lysosomal storage diseases. Acta Paediatr Jpn 1994; 36(1): 30-6.
[PMID: 8165905]
[33]
Miniero R, Busca A, Vassallo E, Madon E. Use of G-CSF in a patient with Hunter syndrome receiving bone marrow transplantation. Am J Hematol 1994; 47(1): 59-60.
[http://dx.doi.org/10.1002/ajh.2830470113] [PMID: 7518996]
[34]
Coppa GV, Gabrielli O, Cordiali R, Villani GR, Di Natale P. Bone marrow transplantation in a Hunter patient with P266H mutation. Int J Mol Med 1999; 4(4): 433-6.
[http://dx.doi.org/10.3892/ijmm.4.4.433] [PMID: 10493987]
[35]
McKinnis EJ, Sulzbacher S, Rutledge JC, Sanders J, Scott CR. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996; 129(1): 145-8.
[http://dx.doi.org/10.1016/S0022-3476(96)70202-0] [PMID: 8757575]
[36]
Li P, Thompson JN, Hug G, Huffman P, Chuck G. Biochemical and molecular analysis in a patient with the severe form of Hunter syndrome after bone marrow transplantation. Am J Med Genet 1996; 64(4): 531-5.
[http://dx.doi.org/10.1002/(SICI)1096-8628(19960906)64:4<531:AID-AJMG1>3.0.CO;2-S] [PMID: 8870917]
[37]
Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997; 76(2): 92-9.
[http://dx.doi.org/10.1136/adc.76.2.92] [PMID: 9068295]
[38]
Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999; 22(5): 638-48.
[http://dx.doi.org/10.1023/A:1005525931994] [PMID: 10399096]
[39]
Tokimasa S, Ohta H, Takizawa S, et al. Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience. Pediatr Transplant 2008; 12(6): 672-6.
[http://dx.doi.org/10.1111/j.1399-3046.2007.00876.x] [PMID: 18798361]
[40]
Boelens JJ, Wynn RF, O’Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007; 40(3): 225-33.
[http://dx.doi.org/10.1038/sj.bmt.1705718] [PMID: 17529997]
[41]
Bartelink IH, van Reij EML, Gerhardt CE, et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2014; 20(3): 345-53.
[http://dx.doi.org/10.1016/j.bbmt.2013.11.027] [PMID: 24315842]
[42]
Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010; 3(3): 285-99.
[http://dx.doi.org/10.1586/ehm.10.21] [PMID: 20871781]
[43]
Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant 2015; 21(6): 1106-9.
[http://dx.doi.org/10.1016/j.bbmt.2015.02.011] [PMID: 25708213]
[44]
CONITEC. Ampliação do Transplante de Células-Tronco Hematopoiéticas para Mucopolissacaridose Tipo II No300. Brasília 2018. Available from: http://conitec.gov.br
[45]
Selvanathan A, Ellaway C, Wilson C, Owens P, Shaw PJ, Bhattacharya K. Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in mucopolysaccharidosis Type II: A Case Series 2018.
[http://dx.doi.org/10.1007/8904_2018_104]
[46]
Tichelli A, Rovó A. Fertility issues following hematopoietic stem cell transplantation. Expert Rev Hematol 2013; 6(4): 375-88.
[http://dx.doi.org/10.1586/17474086.2013.816507] [PMID: 23991924]
[47]
Deduve C. From cytases to lysosomes. Fed Proc 1964; 23: 1045-9.
[PMID: 14209796]
[48]
Ueda K, Hokugo J. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan. Expert Opin Drug Saf 2020; 19(7): 891-901.
[http://dx.doi.org/10.1080/14740338.2020.1751120] [PMID: 32342708]
[49]
Di Ferrante N, Nichols BL, Donnelly PV, Neri G, Hrgovcic R, Berglund RK. Induced degradation of glycosaminoglycans in Hurler’s and Hunter’s syndromes by plasma infusion. Proc Natl Acad Sci USA 1971; 68(2): 303-7.
[http://dx.doi.org/10.1073/pnas.68.2.303] [PMID: 5277074]
[50]
Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8(8): 465-73.
[http://dx.doi.org/10.1097/01.gim.0000232477.37660.fb] [PMID: 16912578]
[51]
Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet 2017; 62(2): 167-74.
[http://dx.doi.org/10.1038/jhg.2016.133] [PMID: 27829684]
[52]
da Silva EM, Strufaldi MWL, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev 2016; 2CD008185
[http://dx.doi.org/10.1002/14651858.CD008185.pub4] [PMID: 26845288]
[53]
Bradley LA, Haddow HRM, Palomaki GE. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review. Genet Med 2017; 19(11): 1187-201.
[http://dx.doi.org/10.1038/gim.2017.30] [PMID: 28640238]
[54]
Parini R, Rigoldi M, Tedesco L, et al. Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients. Mol Genet Metab Rep 2015; 3: 65-74.
[http://dx.doi.org/10.1016/j.ymgmr.2015.03.011] [PMID: 26937399]
[55]
Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011; 13(2): 95-101.
[http://dx.doi.org/10.1097/GIM.0b013e3181fea459] [PMID: 21150784]
[56]
Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2017; 40(6): 867-74.
[http://dx.doi.org/10.1007/s10545-017-0075-x] [PMID: 28887757]
[57]
Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci 2020; 21(8): 21.
[http://dx.doi.org/10.3390/ijms21082975] [PMID: 32340185]
[58]
Ahn SY, Chang YS, Sung DK, et al. High-dose enzyme replacement therapy attenuates cerebroventriculomegaly in a mouse model of mucopolysaccharidosis type II. J Hum Genet 2013; 58(11): 728-33.
[http://dx.doi.org/10.1038/jhg.2013.92] [PMID: 24005894]
[59]
Barbier AJ, Bielefeld B, Whiteman DAH, Natarajan M, Pano A, Amato DA. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab 2013; 110(3): 303-10.
[http://dx.doi.org/10.1016/j.ymgme.2013.08.002] [PMID: 23988379]
[60]
Kim J, Park MR, Kim DS, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy 2013; 68(6): 796-802.
[http://dx.doi.org/10.1111/all.12155] [PMID: 23621439]
[61]
Kim KH, Messinger YH, Burton BK. Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II. Mol Genet Metab Rep 2014; 2: 20-4.
[http://dx.doi.org/10.1016/j.ymgmr.2014.11.007] [PMID: 28649520]
[62]
Calias P, Papisov M, Pan J, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 2012; 7(1)e30341
[http://dx.doi.org/10.1371/journal.pone.0030341] [PMID: 22279584]
[63]
Giugliani R, Dalla Corte A, Poswar F, et al. Intrathecal/Intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects. Expert Opin Orphan Drugs 2018; 6: 403-11.
[http://dx.doi.org/10.1080/21678707.2018.1487838]
[64]
Sohn YB, Ko A-R, Seong M-R, et al. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology. J Inherit Metab Dis 2018; 41(6): 1235-46.
[http://dx.doi.org/10.1007/s10545-018-0221-0] [PMID: 29978271]
[65]
Higuchi T, Shimizu H, Fukuda T, et al. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol Genet Metab 2012; 107(1-2): 122-8.
[http://dx.doi.org/10.1016/j.ymgme.2012.05.005] [PMID: 22704483]
[66]
Sohn YB, Lee J, Cho SY, et al. Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice. Am J Med Genet A 2013; 161A(5): 1036-43.
[http://dx.doi.org/10.1002/ajmg.a.35869] [PMID: 23529876]
[67]
Felice BR, Wright TL, Boyd RB, et al. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol 2011; 39(5): 879-92.
[http://dx.doi.org/10.1177/0192623311409595] [PMID: 21628718]
[68]
Muenzer J, Hendriksz CJ, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 2016; 18(1): 73-81.
[http://dx.doi.org/10.1038/gim.2015.36] [PMID: 25834948]
[69]
Muenzer J, Burton BK, Harmatz P, et al. Efficacy and safety of intrathecal idursulfase in pediatric patients with mucopolysaccharidosis type II and early cognitive impairment: Design and methods of a controlled, randomized, phase II/III multicenter study. Mol Genet Metab 2018; 123: S99-S100.
[http://dx.doi.org/10.1016/j.ymgme.2017.12.262]
[70]
Shire announces top-line results for phase ii/iii clinical trial in children with hunter syndrome and cognitive impairment Available from: https://www.shire.com/en/newsroom/2017/december/wvdwq3
[71]
Pardridge WM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem 2008; 19(7): 1327-38.
[http://dx.doi.org/10.1021/bc800148t] [PMID: 18547095]
[72]
Lu JZ, Hui EK-W, Boado RJ, Pardridge WM. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem 2010; 21(1): 151-6.
[http://dx.doi.org/10.1021/bc900382q] [PMID: 20000684]
[73]
Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 1995; 12(6): 807-16.
[http://dx.doi.org/10.1023/A:1016244500596] [PMID: 7667183]
[74]
Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng 2014; 111(11): 2317-25.
[http://dx.doi.org/10.1002/bit.25289] [PMID: 24889100]
[75]
Sonoda H, Morimoto H, Yoden E, et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther 2018; 26(5): 1366-74.
[http://dx.doi.org/10.1016/j.ymthe.2018.02.032] [PMID: 29606503]
[76]
Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: A phase 1/2 trial. Mol Ther 2019; 27(2): 456-64.
[http://dx.doi.org/10.1016/j.ymthe.2018.12.005] [PMID: 30595526]
[77]
Moskot M, Jakóbkiewicz-Banecka J, Kloska A, et al. Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids. Sci Rep 2015; 5: 9378.
[http://dx.doi.org/10.1038/srep09378] [PMID: 25797591]
[78]
Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, et al. Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011; 17(4): CR196-202.
[http://dx.doi.org/10.12659/MSM.881715] [PMID: 21455105]
[79]
de Ruijter J, Valstar MJ, Narajczyk M, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012; 71(1): 110-20.
[http://dx.doi.org/10.1002/ana.22643] [PMID: 22275257]
[80]
Friso A, Tomanin R, Salvalaio M, Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010; 159(5): 1082-91.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00565.x] [PMID: 20136838]
[81]
Marucha J, Tylki-Szymańska A, Jakóbkiewicz-Banecka J, et al. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am J Med Genet A 2011; 155A(9): 2257-62.
[http://dx.doi.org/10.1002/ajmg.a.34146] [PMID: 21834048]
[82]
Fumić B, Jablan J, Cinčić D, Zovko Končić M, Jug M. Cyclodextrin encapsulation of daidzein and genistein by grinding: implication on the glycosaminoglycan accumulation in mucopolysaccharidosis type II and III fibroblasts. J Microencapsul 2018; 35(1): 1-12.
[http://dx.doi.org/10.1080/02652048.2017.1409819] [PMID: 29168930]
[83]
Derrick-Roberts ALK, Jackson MR, Pyragius CE, Byers S. Substrate deprivation therapy to reduce glycosaminoglycan synthesis improves aspects of neurological and skeletal pathology in mps I mice. Diseases 2017; 5(1): 5.
[http://dx.doi.org/10.3390/diseases5010005] [PMID: 28933358]
[84]
Donida B, Marchetti DP, Biancini GB, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta 2015; 1852(5): 1012-9.
[http://dx.doi.org/10.1016/j.bbadis.2015.02.004] [PMID: 25701642]
[85]
Jacques CED, Donida B, Mescka CP, et al. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation. Biochim Biophys Acta 2016; 1862(9): 1608-16.
[http://dx.doi.org/10.1016/j.bbadis.2016.05.021] [PMID: 27251652]
[86]
Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 2010; 107(1): 222-7.
[http://dx.doi.org/10.1073/pnas.0912937107] [PMID: 20018674]
[87]
Polgreen LE, Kunin-Batson A, Rudser K, et al. Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II. Mol Genet Metab Rep 2017; 10: 75-80.
[http://dx.doi.org/10.1016/j.ymgmr.2017.01.002] [PMID: 28119823]
[88]
Hennermann JB, Gökce S, Solyom A, Mengel E, Schuchman EH, Simonaro CM. Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis 2016; 39(6): 831-7.
[http://dx.doi.org/10.1007/s10545-016-9974-5] [PMID: 27590017]
[89]
Parker H, Bigger BW. The role of innate immunity in mucopolysaccharide diseases. J Neurochem 2019; 148(5): 639-51.
[PMID: 30451296]
[90]
Entchev E, Jantzen I, Masson P, et al. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models. PLoS One 2020; 15(5)e0233032
[http://dx.doi.org/10.1371/journal.pone.0233032] [PMID: 32413051]
[91]
Friso A, Tomanin R, Alba S, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med 2005; 7(11): 1482-91.
[http://dx.doi.org/10.1002/jgm.790] [PMID: 15966019]
[92]
Friso A, Tomanin R, Zanetti A, et al. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS). Biochim Biophys Acta 2008; 1782(10): 574-80.
[http://dx.doi.org/10.1016/j.bbadis.2008.07.001] [PMID: 18675343]
[93]
Cardone M, Polito VA, Pepe S, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 2006; 15(7): 1225-36.
[http://dx.doi.org/10.1093/hmg/ddl038] [PMID: 16505002]
[94]
Baldo G, Giugliani R, Matte U. Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy. Med Hypotheses 2014; 82(4): 478-80.
[http://dx.doi.org/10.1016/j.mehy.2014.01.029] [PMID: 24560457]
[95]
Hinderer C, Katz N, Louboutin J-P, et al. delivery of an adeno-associated virus vector into cerebrospinal fluid attenuates central nervous system disease in mucopolysaccharidosis type II mice. Hum Gene Ther 2016; 27(11): 906-15.
[http://dx.doi.org/10.1089/hum.2016.101] [PMID: 27510804]
[96]
Laoharawee K, Podetz-Pedersen KM, Nguyen TT, et al. Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, aav9-mediated iduronate sulfatase gene transfer. Hum Gene Ther 2017; 28(8): 626-38.
[http://dx.doi.org/10.1089/hum.2016.184] [PMID: 28478695]
[97]
Motas S, Haurigot V, Garcia M, et al. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight 2016; 1(9)e86696
[http://dx.doi.org/10.1172/jci.insight.86696] [PMID: 27699273]
[98]
Wakabayashi T, Shimada Y, Akiyama K, et al. Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II. Hum Gene Ther 2015; 26(6): 357-66.
[http://dx.doi.org/10.1089/hum.2014.158] [PMID: 25761450]
[99]
Gleitz HF, Liao AY, Cook JR, et al. Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms. EMBO Mol Med 2018; 10(7): 10.
[http://dx.doi.org/10.15252/emmm.201708730] [PMID: 29884617]
[100]
Sharma R, Anguela XM, Doyon Y, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 2015; 126(15): 1777-84.
[http://dx.doi.org/10.1182/blood-2014-12-615492] [PMID: 26297739]
[101]
Sheridan C. Sangamo’s landmark genome editing trial gets mixed reception. Nat Biotechnol 2018; 36(10): 907-8.
[http://dx.doi.org/10.1038/nbt1018-907] [PMID: 30307929]
[102]
Alliegro M, Ferla R, Nusco E, De Leonibus C, Settembre C, Auricchio A. Low-dose gene therapy reduces the frequency of enzyme replacement therapy in a mouse model of lysosomal storage disease. Mol Ther 2016; 24(12): 2054-63.
[http://dx.doi.org/10.1038/mt.2016.181] [PMID: 27658524]
[103]
Giugliani R, Villarreal MLS, Valdez CAA, et al. Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America. Genet Mol Biol 2014; 37(2): 315-29.
[http://dx.doi.org/10.1590/S1415-47572014000300003] [PMID: 25071396]
[104]
Scarpa M, Almássy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011; 6: 72.
[http://dx.doi.org/10.1186/1750-1172-6-72] [PMID: 22059643]
[105]
Berger KI, Fagondes SC, Giugliani R, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36(2): 201-10.
[http://dx.doi.org/10.1007/s10545-012-9555-1] [PMID: 23151682]
[106]
Gönüldaş B, Yılmaz T, Sivri HS, et al. Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway. Int J Pediatr Otorhinolaryngol 2014; 78(6): 944-9.
[http://dx.doi.org/10.1016/j.ijporl.2014.03.021] [PMID: 24731921]
[107]
Chiong MAD, Canson DM, Abacan MAR, Baluyot MMP, Cordero CP, Silao CLT. Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome. Orphanet J Rare Dis 2017; 12(1): 7.
[http://dx.doi.org/10.1186/s13023-016-0558-0] [PMID: 28077157]
[108]
Rutten M, Ciet P, van den Biggelaar R, et al. Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis. Orphanet J Rare Dis 2016; 11: 50.
[http://dx.doi.org/10.1186/s13023-016-0425-z] [PMID: 27112191]
[109]
Harrison R, Schaefer S, Warner L, Mercer J, Jones S, Bruce I. Transnasal adenoidectomy in mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol 2018; 111: 149-52.
[http://dx.doi.org/10.1016/j.ijporl.2018.04.028] [PMID: 29958599]
[110]
Jeong H-S, Cho D-Y, Ahn KM, Jin D-K. Complications of tracheotomy in patients with mucopolysaccharidoses type II (Hunter syndrome). Int J Pediatr Otorhinolaryngol 2006; 70(10): 1765-9.
[http://dx.doi.org/10.1016/j.ijporl.2006.05.021] [PMID: 16831472]
[111]
Dvorakova L, Vlaskova H, Sarajlija A, et al. Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II. Clin Genet 2017; 91(5): 787-96.
[http://dx.doi.org/10.1111/cge.12927] [PMID: 27883178]
[112]
Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in Hunter syndrome. J Pediatr 2011; 159(2): 327-31.e2.
[http://dx.doi.org/10.1016/j.jpeds.2011.01.054] [PMID: 21529823]
[113]
Alkhzouz C, Lazea C, Bucerzan S, et al. Clinical and genetic characteristics of romanian patients with mucopolysaccharidosis type II. JIMD Rep 2017; 33: 19-25.
[http://dx.doi.org/10.1007/8904_2016_535] [PMID: 27351199]
[114]
Braunlin E, Wang R. Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs. Heart 2016; 102(16): 1257-62.
[http://dx.doi.org/10.1136/heartjnl-2015-309258] [PMID: 27102649]
[115]
Manara R, Priante E, Grimaldi M, et al. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. J Inherit Metab Dis 2011; 34(3): 763-80.
[http://dx.doi.org/10.1007/s10545-011-9317-5] [PMID: 21465231]
[116]
Dalla Corte A, de Souza CFM, Anés M, Giugliani R. Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know? Childs Nerv Syst 2017; 33(7): 1073-80.
[http://dx.doi.org/10.1007/s00381-017-3476-0] [PMID: 28593554]
[117]
Kwon J-Y, Ko K, Sohn YB, et al. High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome). Am J Med Genet A 2011; 155A(6): 1329-35.
[http://dx.doi.org/10.1002/ajmg.a.34013] [PMID: 21567931]
[118]
Aslam R, Hendriksz CJ, Jester A. Objective results of median nerve decompression and tenosynovectomy for carpal tunnel syndrome in patients with mucopolysaccharidoses Types I and II. J Hand Surg Eur Vol 2015; 40(2): 216-8.
[http://dx.doi.org/10.1177/1753193414523356] [PMID: 24554690]
[119]
Okuyama T, Kosuga M, Hamazaki T, Shintaku H, Seo J-H. Investigator-initiated clinical trial of intra-cerebroventricular enzyme replacement therapy for neuronopathic mucopolysaccharidosis type II. Mol Genet Metab 2018; 123: S109.
[http://dx.doi.org/10.1016/j.ymgme.2017.12.289]

Rights & Permissions Print Cite
Article Metrics
29
© 2024 Bentham Science Publishers | Privacy Policy